NCT05427253View on ClinicalTrials.gov

First-in-human Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of C106 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

80

Participants

Timeline

Start Date

June 8, 2022

Primary Completion Date

June 22, 2023

Study Completion Date

June 22, 2023

Conditions
Safety IssuesToleranceIdiopathic Pulmonary FibrosisPulmonary Hypertension
Interventions
DRUG

C106 solution

selective nonpeptide angiotensin II type 2 receptor (AT2R) agonist

DRUG

Placebo

Placebo for C106 solution

Trial Locations (1)

SE-752 37

CTC Clinical Trial Consultants AB, Uppsala

All Listed Sponsors
lead

Vicore Pharma AB

INDUSTRY